(46 from the somatic and 60 from the germline model) were taken from animals without mobilized transposons for histopathological review. Tumors were larger and more numerous in Apc fl/+ animals with mobilized transposons (Fig. 1c) . The majority of tumors were oligocryptal and tubulovillous adenomas (Supplementary Table 1) . However, some tumors from the somatic model with mobilized transposons had moderate or severe dysplasia (N = 40 and 23 mice, respectively), and 10 tumors showed evidence of invasion (N = 9 mice) ( Fig. 1e-g ). Both somatic and germline models produced microsatellite stable tumors (Supplementary Fig. 3 ).
Identification of common insertion sites of Sleeping Beauty
In total, we identified 146,249 non-redundant transposon insertion sites (an average of 328 per tumor) after 454 sequencing and mapping to the mouse genome. We employed two statistical frameworks to determine CISs: Monte Carlo simulations and a Gaussian kernel convolution (GKC) algorithm that were both optimized to take into account the TA nucleotide bias of the Sleeping Beauty transposon 8, 18, 19 . To maximize statistical power, we pooled insertions from both the Apc fl and Apc min models. The concordance between the two statistical methods was 60%, according to results from overlapping CIS regions; Monte Carlo analysis identified 749 CISs, and GKC analysis with 30-kb and 120-kb kernel sizes identified 919 and 641 CISs, respectively, for a total of 997 unique CIS regions in 867 genes ( Supplementary  Table 2a-d) . The results of the GKC analysis were used to define a discovery set for further analysis and refinement by comparison to other data sets. Notably, the T2/Onc transposon can generate gainof-function mutations by integrating in or near genes and driving overexpression from the MSCV promoter in the transposon. It can also cause loss-of-function mutations by integrating in genes and hijacking transcription by using the splice acceptor and poly(A) signals of the transposon. Insertions may also generate neomorphic alleles or potentially disrupt regulatory elements around cancer gene loci. To identify CISs that may have occurred in preferential insertion hotspots, we mobilized transposons as described above and collected a total of 48 tissue samples for insertion site analysis 2 weeks and 10 months after mobilization. Sequencing of the insertions from these tissues yielded 17,358 unique insertions and 35 CISs by GKC analysis. Only 1.8% of CISs called from the tumors overlapped with the control CISs (Supplementary Table 2e ). Analysis of CISs associated with known cancer genes allowed us to establish a set of rules to assign insertions to genes. These rules are outlined in the Supplementary Note (see also Supplementary Figs. 
4-9, Supplementary Tables 3 and 4 and Supplementary Data 1-5).

Tumor etiology
Of note, our results indicated that there is positive selection for hundreds of candidate cancer genes following insertional mutagenesis. Considering tumor etiology is important in understanding this observation. We determined that multiple tumors obtained from individual mice were biologically independent, as their insertions were no more likely to be in the same genomic location than were insertions in tumors from different mice ( Supplementary  Fig. 10 ). Therefore, separate lesions taken from the same mouse intestine evolve independently. Further, when examining Apc (mutated in 91.3% of tumors), we observed that not only is mutation of the second allele a near obligate event in the Apc-driven model of tumorigenesis, but also Apc is recurrently mutated (65% of tumors had three or more insertions in Apc). These multiple alterations to Apc must arise from selection for serial truncating mutations within this gene during tumor development, as has been shown for the attenuated form of familial adenomatous polyposis (Fig. 1a) , the rate of insertional mutagenesis is less than one event per cell per week (although the presence of contaminating stromal cells in which the transposase is not activated may mean that this rate is an underestimate). Thus, transposon mobilization is inefficient and ongoing throughout tumorigenesis, with the extensive accumulated mutational burden arising from selective forces. This process leads to the development of oligoclonal tumors and explains in part the large number of insertions we identified. Consequently, many mutated genes make a relatively small contribution to tumor growth. Overall, the average number of insertions per tumor that contributed to a CIS was 1.14, indicating that some tumors contained multiple insertions contributing to a CIS (Supplementary Table 5a-d). For example, 5.4% of tumors had two or more insertions in Ctnnd1, 4.7% of tumors had two or more insertions in Kcnq1, and 4.0% of tumors had two or more insertions in Lass6. These multiple insertions may be due to the presence of multiple independent tumor subclones within the tumor bulk, suggesting that the mutation of these genes may represent a bottleneck in tumor evolution whereby individual cells within the tumor acquire different mutations in order to progress. This observation is also consistent with these genes functioning as tumor suppressors, requiring biallelic mutations before they become operative in cancer development 21 . We cannot currently distinguish between these possibilities.
Other frequently mutated CIS-targeted genes previously implicated in intestinal cancer include Pten, Smad4 and Bmpr1a, which were mutated in a significant number of tumors in our study (13.2%, 15.7% and 7.6%, respectively; P < 1.51 × 10 −5 ), showing that transposons mutate the same genes that are disrupted in the human disease. In 48 tumors with single insertions in Pten, Smad4 and Bmpr1a, we sequenced the coding regions of these genes and found no further spontaneous mutations, indicating that the insertions in these genes may be acting in a haploinsufficient manner (data not shown).
Transposons drive tumorigenesis via conserved pathways
To evaluate the types of genes involved in tumorigenesis and to facilitate the filtering of the discovery set of CIS-targeted genes, we used Ingenuity pathway analysis. We determined that the CIScontaining genes identified in our screen were significantly enriched for components of cancer-associated signaling pathways, accounting for 113 genes. For example, genes in the PI3K-Akt, ERK-MAPK, Wnt and integrin signaling pathways were enriched for mutations (P = 2.69 × 10 −8 , 2.76 × 10 −8 , 2.13 × 10 −7 and 1.39 × 10 −7 , respectively) (Supplementary Table 6 ). Loss-of-function mutations, characterized by intragenic transposon insertions in either orientations, appeared to predominate. Insertions near Kras, whose human homolog is mutated in around 40% of sporadic human colorectal carcinomas, were present in only 5% of tumors 22, 23 . In addition, mutations in Trp53 and Smad4 were found at frequencies of only 5.2% and 15.7%, respectively. To assess the ability of our insertional mutagenesis screen to exploit the K-Ras, p53 and TGF-β signaling pathways, we examined insertions in CISs associated with genes immediately up-or downstream of these key cancer drivers in each signaling cascade and determined that they were frequently mutated (all with P ≤ 2.23 × 10 −5 ) (Fig. 2) . In total, 38.6% of tumors carried mutations in genes in the K-Ras pathway, 48.0% in the TGF-β pathway and 61.4% in the p53 pathway. Just under half of all tumors carried mutations in CISs associated with genes in more than one of these pathways, with 15.9% carrying mutations in all three (Fig. 2) .
Tumor pathology along with the number or type of pathways mutated showed no correlation with more dysplastic disease (data not shown). However, some CIS-targeted genes were over-represented in tumors carrying insertions in these pathways (around 40, 43 and 36 CIS-targeted genes for the K-Ras, p53 and TGF-β signaling pathways, respectively; Supplementary Tables 7-9 ). Therefore, transposon insertions drive tumorigenesis using the same conserved pathways that are operative in human cancers, and, where perturbed, these pathways are associated with additional gene insertions. 
A r t i c l e s
Cross-species comparison
Human cancer genomes acquire mutations that not only drive tumorigenesis but also reflect the signatures of the mutagenic processes that underlie their evolution 7 . Using cross-species oncogenomics, we compared the CISs identified in this study to human CRC data sets to implicate up to 234 CIS-targeted genes in the human disease ( Fig.3a and Supplementary Tables 10-14) . Genes overlapping in two or more of the data sets (34 genes) were distributed throughout the CIS list and include genes known to be important in colorectal carcinoma, Fig. 11 and Supplementary Table 19 ). Of note, an additional 10 proteins encoded by CIS-containing genes overlap with overexpressed proteins and transcripts identified in a screen of adenomas from Apc min/+ mice 24, 25 , including Cul1 and Pdlim1. Furthermore, recent studies using intercrosses with Apc min/+ mice have shown that Pparg, Pten, *** *** * *** ** *** **** *** *** ** * * *** * * * ** *** *** *** 44 to generate a final set of CIS-containing genes for further study. SW480 cells containing a stably integrated β-lactamase reporter gene under the control of the LEF and TCF consensus binding sequence were transiently transfected with siRNA (final concentration of 20 nM) and processed after 72 h. Fluorescence resonance energy transfer (FRET) analysis was performed, and the fold change represented in the graph was calculated relative to the GC control. Error bars show s.d, N = 4. Data were pooled from three independent experiments to determine statistical significance by the Student's t test (*P < 0.05, **P < 0.01, ***P < 0.001).
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A r t i c l e s
Rb1, Mapk1, Stat3, Ephb4, Myb, Cd44 and Smad3 cooperate with Apc loss in intestinal tumorigenesis, and all of these genes were detected in our analysis [26] [27] [28] [29] [30] [31] [32] [33] [34] . Finally, comparison of our data with an arraycomparative genomic hybridization (CGH) data set from spontaneously evolving tumors in Apc min/+ mice showed a significant overlap between genes we identified as having CISs and regions rearranged in tumors from the Apc min/+ mice (P = 6.75 × 10 −7 ) (Supplementary Note) 35 , suggesting that transposons target the same genes that are disrupted in spontaneous cancers. Notably, 224 genes were predicted to be disrupted in each of these spontaneous mouse tumors, which is threefold higher than the average number of CISs per tumor (76).
Association of CIS genes with the Wnt pathway
The observation that there was enrichment for subsets of CIScontaining genes in tumors with mutations affecting the p53, K-Ras and Wnt pathways suggested that one explanation for so many potential cancer drivers is their modulation of known cancer pathways. To test this theory functionally, we examined one such pathway, namely the Wnt signaling pathway. The presence of TCF and β-catenin consensus binding sites in the promoter regions of 183 CIS-targeted genes suggested that they are potential Wnt targets (P = 1.1 × 10 −64 ; TRANSFAC 2009.3, BIOBASE GmBH) 36 . Of these, 37 genes showed significant copy-number changes in an array-CGH analysis of human CRCs ( Fig. 3 and Supplementary Table 20) and were assessed to determine whether they were potential modulators of Wnt signaling. We used the CellSensor Wnt reporter system in SW480 CRC cells in conjunction with siRNA knockdown of the candidate Wnt modulators and identified 16 genes encoding negative regulators of Wnt signaling and 4 encoding positive regulators (Fig. 4) . To control for off-target effects of the siRNA, we tested nine randomly selected siRNAs and found that they had no effect on Wnt reporter activity (Supplementary Fig. 12) . Overall, these data show a significant enrichment for genes that regulate canonical Wnt signaling in our insertional mutagenesis screen (P < 0.005, Fisher's exact test) (Supplementary Note). The E3 ubiquitin ligase NEDD4, known to polyubiquinate the tumor suppressor PTEN, appears to negatively regulate Wnt signaling, suggesting a potential link between two distinct tumor suppressor mechanisms involving APC and PTEN. Rcor1, Onecut2 and Zfpm1 encode transcription factors, the knockdown of which caused a robust increase in Wnt signaling, thus confirming a regulatory role for these factors in the Wnt pathway. A subset of human CRCs containing an increased proportion of Paneth cells has been described 37 . In the present study, pathological inspection identified Paneth cell differentiation in a substantial number of tumors (83/367) (Fig. 1h) . Mouse models in which germline Apc mutations were engineered to retain a single domain of APC that functions in β-catenin binding and degradation, so as to retain some residual functionality from the truncated allele (mutation at T1322), have also been shown to carry tumors with a higher proportion of Paneth cells and a more dysplastic phenotype 38 . Thirty-six of our CISs CISs that are not located within 150 kb of a gene are labeled as CIS followed by the chromosome, the peak location of the Gaussian kernel and the kernel size. were identified as being over-represented in this group when compared to non-Paneth cell tumors ( Table 1) . Of these, eight have previously been identified as Wnt targets 36 . Of note, Eps8, which we showed to be a positive regulator of the Wnt pathway (Fig. 4) , is also a CIS-containing gene that was enriched for in the tumors with a higher proportion of Paneth cells. Three of the 36 genes (Usp10, Eps8 and Cask) have been shown to be upregulated in the intestine showing an increase in Paneth cell number due to deletion of Klf9 (ref. 39). These results further demonstrate the importance of fine-tuning Wnt signaling throughout tumor development, with one outcome being altered tumor pathology.
We also compared tumors that were histopathologically classified as presenting with either mild or moderate atypia (N = 332) with those showing moderate or severe dysplasia (N = 35); 23 genes were overrepresented in the tumors with a more severe phenotype, suggesting that these genes contribute to disease progression ( Table 2) . Genes involved in fibroblast growth factor (FGF) signaling (Frs2 and Grb2) were found to contain CISs in tumors with a more severe phenotype. It has been proposed that activation of this pathway in coordination with Wnt signaling results in a more malignant phenotype 40 . Among others on the list of genes associated with moderate or severe dysplasia, Uhrf2 has been associated with an increased risk of colon cancer 41 , and a gene fusion of Tmprss2 (Tmprss2-Erg1) has been associated with a poor prognosis in prostate cancer 42 . Slk encodes a serinethreonine protein kinase that, when complexed with Asap1, promotes CRC metastasis 43 . Therefore, these over-represented genes may provide new insights into the mechanisms of CRC progression.
Co-occurrence of CISs within genes
We also identified co-occurring CISs (co-CISs), in which two CISs were co-mutated at a higher frequency than expected by chance. As expected, the majority of co-CISs we identified were associated with Apc, as mutation of the wild-type allele of Apc is a near obligate event in adenomagenesis in our model. We focused on other co-CISs and identified 70 CIS-containing genes involved in statistically significant pairwise co-occurrences that made up 38 networks, the largest containing 28 genes (Fig. 5 and Supplementary Table 21) . Several of the interactions identified were within CISs associated with known tumor suppressor genes, such as the interaction of Lrrc41 with Pten and Lamp1 with the Smad4-Mex3c locus (Fig. 4) . Analysis of human array-CGH data provided independent support for the interactions of two of the co-CISs: those between the Smad4-Mex3c locus and Lamp1 and between Sfi1 and Adnp (Supplementary Table 20) 44 . At the center of the largest network, we found the CIS in Atp6v0a2-Tctn2. Tctn2 has previously been shown to be mutated in both mouse and human CRCs 35 . Of note, these networks include genes in which insertions co-occur with insertions in well-established cancer drivers such as Pten, Smad4 and Rac1.
DISCUSSION
We have performed an extensive forward genetic screen in the intestinal tract using mouse models of somatic and germline neoplasia. These studies identified hundreds of genes and 38 genetic networks composed of these genes that are candidate drivers of carcinogenesis. The value of this discovery set will ultimately be established by the application of high-throughput mutation data from human colon cancers to this framework. However, it is worth noting that our screen identified genes recently found to be mutated in human CRCs 44, 45 , including MLL3 and CDK8. In line with previous commentaries that implicate selection pressures and not elevated mutation rates in driving tumorigenesis, we confirm that the Sleeping Beauty transposon is inefficiently mobilized, generating a very low rate of cellular mutagenesis 46 . The high number of accumulated mutations observed is thus a consequence of selection acting on increasingly diverse populations to create highly oligoclonal tumors.
Using cross-species oncogenomics, we independently implicated approximately one-third of our CIS-containing genes in colorectal neoplasia in human studies. Functionally, we identified 20 new regulators of Wnt signaling, implicating these genes in colorectal tumorigenesis through control of this pathway. Collectively, our analysis provides a rich catalog of candidate genes that represent potential diagnostic, prognostic and therapeutic targets and defines the breadth of genes that may contribute to cancer of the intestine. Our screen is in agreement with a previous exome resequencing study of human CRCs that predicted many hundreds of functional mutations in human cancer 47 .
The number of genes identified in our screen suggests that many more genes than previously thought can contribute to CRC development if appropriately altered. Others have suggested that approximately ten genes in any one cancer may drive tumorigenesis, with each cancer carrying common driver mutations and also rarer mutations that may additionally contribute to cancer progression [1] [2] [3] 7 . Determining which genes are drivers is complicated by a lack of knowledge of the functional significance of the many hundreds of infrequent somatic alterations that are acquired during cancer development and because, at present, no study has systematically analyzed the landscape of somatic mutations in a human cancer type in a large number of samples at base-pair resolution. In this screen, we used Figure 5 Co-occurring CISs can be grouped into interacting networks. CISs generated from the 30-kb and 120-kb GKC analyses were merged, and pairwise comparisons between each CIS were performed. Contingency tables were constructed for each comparison, and a Fisher's exact test was performed. To account for multiple testing, a Q value was generated for each test and adjusted P values of P < 0.05 were reported. This analysis generated 70 coordinate relationships in 38 networks, 3 of which are shown. CISs are represented by the nearest associated gene, and the thickness of each interconnecting line between two genes represents the level of significance of the co-occurrence. A r t i c l e s a transposon that must integrate proximally to a gene to function, and in this way we identified candidate cancer genes when they were mutated at a frequency higher than expected by chance. Whereas genes that are infrequently mutated in human cancer and in our screen are less likely to be major players in tumorigenesis, population theory suggests that any genetic alteration that causes a fractional increase in the ability of a cell to outgrow other cells may contribute to tumorigenesis 48, 49 . The classical model for this is yeast, in which as many as 6% of mutations that alter the growth kinetics of a population of cells can result in the outgrowth of a more vigorous population 50 . Likewise, in human studies, there is evidence to suggest that mutations that fractionally increase the fitness of a cell within a population can predispose that cell to evolve into a transformed cell 51 . In this way, many of the genes that we have discovered in this screen may contribute independently or in combination to tumor development. This interpretation of our study is supported by several lines of evidence. First, we have shown that the majority of cancers in our screen carried mutations in Apc and, furthermore, that 20 genes can modify canonical Wnt signaling, even in tumor cell lines in which Apc is already disrupted. There is a long-standing observation that the second somatic hit that affects APC in sporadic and familial CRCs is influenced by the nature of the first mutation, such that at least one β-catenin-binding domain is retained in one allele. The interpretation is that the complete loss of Apc function is not tolerated by the normal epithelium (the 'just-right' phenomenon). Hence, the initial transformation event does not give 'maximal' dysregulation of the pathway 52 . Loss-of-function mutations in SFRP genes (encoding Wnt antagonists) in human CRCs have been found to increase Wnt signaling to higher levels than result from the initiating APC mutation 53, 54 . Moreover, one of the key effects of both Kras and Braf mutations is to synergize with Apc mutations by enhancing Wnt signaling 55 . In short, it is well established that the dysregulation of Wnt signaling is not a single event but is subject to modulation throughout cancer development. The fine-tuning of Wnt signaling is one likely means for achieving fractional increases in fitness. Second, many of the genes discovered in this screen are associated with known CRC pathways, such as the Wnt, PI3K and Ras cascades. Genes associated with these pathways are significantly enriched for mutations over the level that would be expected by chance. This finding suggests that many of the genes recurrently mutated by transposons are functioning through these pathways to optimize tumor cell growth. Finally, many CIS-targeted genes can be clustered into other pathways using pathway analysis tools, suggesting that, in addition to the main oncogenic routes, other pathways are also operative in bowel cancer that, if appropriately altered, can contribute to tumorigenesis. Follow-up functional analysis will help us gain a better understanding of how the CIS-targeted genes that we have discovered contribute to CRC.
The co-occurring networks of mutated genes discovered from this insertional mutagenesis screen suggest that the mutation of many genes is important in CRC development. However, the presence of coordinately mutated genes in a cancer does not necessarily mean that mutations of these genes function in a cell-autonomous manner to promote cancer growth. Each of the tumors we analyzed is composed of multiple tumor cell clones, and this heterogeneity may favor cellular interactions that result in some of the co-occurrences we observed.
In conclusion, we have shown that insertional mutagenesis in the mouse, performed on a hitherto unprecedented scale, can identify hundreds of candidate cancer driver genes that promote CRC development.
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
